<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC11813630</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC11813630.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">11813630</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">11813630</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">39934085</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1002/jcsm.13719</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">JCSM13719</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="other">JCSM-D-24-00721</article-id></all-ids><extracted-table><table-id>jcsm13719-tbl-0001</table-id><table-label>TABLE 1</table-label><table-caption>Characteristics of included studies.</table-caption><table-wrap-foot>Abbreviations: CDR, Clinical Dementia Rating scale; CHS, Cardiovascular Health Study frailty score; CN, cognitively normal; DSM‐III‐R, Diagnostic and Statistical Manual, third edition revised; DTI, diffusion tensor imaging; EFS, Edmonton frailty scale; fMRI, functional magnetic resonance imaging; IST, Isaacs Set Test; MCI, mildly cognitively impaired; MEG, magnetoencephalography; MMSE, Mini‐Mental State Examination; MRI, magnetic resonance imaging; NINCDS‐ADRDA, National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association; PET, positron emission tomography.aMedian, IQR.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="jcsm13719-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of included studies.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Study design</th><th align="center" valign="bottom" rowspan="1" colspan="1">Country</th><th align="center" valign="bottom" rowspan="1" colspan="1">Study groups (frailty score)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sample size F/M</th><th align="center" valign="bottom" rowspan="1" colspan="1">Age (years) mean ± SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mean MMSE ± SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">Modality</th><th align="center" valign="bottom" rowspan="1" colspan="1">Frailty measurements</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cognitive status</th><th align="center" valign="bottom" rowspan="1" colspan="1">Matched for</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top" colspan="1">Avila‐Funes, 2016</td><td align="center" rowspan="2" valign="top" colspan="1">Cohort</td><td align="center" rowspan="2" valign="top" colspan="1">Mexico</td><td align="center" valign="top" rowspan="1" colspan="1">Robust</td><td align="center" valign="top" rowspan="1" colspan="1">51/92</td><td align="center" valign="top" rowspan="1" colspan="1">75.0 ± 5.0</td><td align="center" valign="top" rowspan="1" colspan="1">27.2 ± 2.1</td><td align="center" rowspan="2" valign="top" colspan="1">MRI, DTI</td><td align="center" rowspan="2" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="2" valign="top" colspan="1">MMSE &gt; 15</td><td align="center" rowspan="2" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail</td><td align="center" valign="top" rowspan="1" colspan="1">19/14</td><td align="center" valign="top" rowspan="1" colspan="1">76.0 ± 5.7</td><td align="center" valign="top" rowspan="1" colspan="1">26.4 ± 2.7</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Chen, 2015</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Taiwan</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">119/140</td><td align="center" valign="top" rowspan="1" colspan="1">62.5 ± 7.7</td><td align="center" valign="top" rowspan="1" colspan="1">26.9 ± 2.9</td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">Dementia excluded based on MMSE score</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">89/89</td><td align="center" valign="top" rowspan="1" colspan="1">65.2 ± 9.0</td><td align="center" valign="top" rowspan="1" colspan="1">25.8 ± 3.4</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">9/10</td><td align="center" valign="top" rowspan="1" colspan="1">73.6 ± 7.4</td><td align="center" valign="top" rowspan="1" colspan="1">23.1 ± 3.8</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Chung, 2016</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Taiwan</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">348/263</td><td align="center" valign="top" rowspan="1" colspan="1">60.34 ± 7.28</td><td align="center" rowspan="3" valign="top" colspan="1">—</td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria, CHS score</td><td align="center" rowspan="3" valign="top" colspan="1"><p>Score &gt; 24 in well‐educated subjects</p><p>MMSE score &gt; 14 in less‐educated subjects</p></td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">173/146</td><td align="center" valign="top" rowspan="1" colspan="1">65.28 ± 9.00</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">16/16</td><td align="center" valign="top" rowspan="1" colspan="1">74.90 ± 7.86</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Ducca, 2022</td><td align="center" rowspan="2" valign="top" colspan="1">Cohort</td><td align="center" rowspan="2" valign="top" colspan="1">United States</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (&lt; 3)</td><td align="center" valign="top" rowspan="1" colspan="1">954/671</td><td align="center" valign="top" rowspan="1" colspan="1">76.0 ± 4.7</td><td align="center" rowspan="2" valign="top" colspan="1">—</td><td align="center" rowspan="2" valign="top" colspan="1">MRI, DTI</td><td align="center" rowspan="2" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="2" valign="top" colspan="1">Participants who did not meet criteria for MCI or dementia according to expert adjudications</td><td align="center" rowspan="2" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">87/42</td><td align="center" valign="top" rowspan="1" colspan="1">78.5 ± 5.5</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Kant, 2019</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Netherlands</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">12/43</td><td align="center" valign="top" rowspan="1" colspan="1">70 ± 4</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">MMSE &gt; 24</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">24/61</td><td align="center" valign="top" rowspan="1" colspan="1">72 ± 5</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">16/14</td><td align="center" valign="top" rowspan="1" colspan="1">74 ± 5</td><td align="center" valign="top" rowspan="1" colspan="1">28</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Suárez‐Méndez, 2020</td><td align="center" rowspan="2" valign="top" colspan="1">Case–control</td><td align="center" rowspan="2" valign="top" colspan="1">Spain</td><td align="center" valign="top" rowspan="1" colspan="1">Robust</td><td align="center" valign="top" rowspan="1" colspan="1">21/13</td><td align="center" valign="top" rowspan="1" colspan="1">78.50</td><td align="center" valign="top" rowspan="1" colspan="1">27.0</td><td align="center" rowspan="2" valign="top" colspan="1">MEG, MRI</td><td align="center" rowspan="2" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="2" valign="top" colspan="1">MMSE &gt; 24</td><td align="center" rowspan="2" valign="top" colspan="1">Age and gender</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail</td><td align="center" valign="top" rowspan="1" colspan="1">15/5</td><td align="center" valign="top" rowspan="1" colspan="1">81</td><td align="center" valign="top" rowspan="1" colspan="1">26.0</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Kant, 2018</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Netherlands</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">24/51</td><td align="center" valign="top" rowspan="1" colspan="1">71.6 ± 4.5</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">MMSE &gt; 24</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">37/70</td><td align="center" valign="top" rowspan="1" colspan="1">72.3 ± 5.0</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">19/13</td><td align="center" valign="top" rowspan="1" colspan="1">74.7 ± 5.4</td><td align="center" valign="top" rowspan="1" colspan="1">28</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Lammers, 2020</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">19/41</td><td align="center" valign="top" rowspan="1" colspan="1">70.5</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" rowspan="3" valign="top" colspan="1">fMRI</td><td align="center" rowspan="3" valign="top" colspan="1">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">MMSE &gt; 24</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">37/33</td><td align="center" valign="top" rowspan="1" colspan="1">71.5</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">8/5</td><td align="center" valign="top" rowspan="1" colspan="1">74.0</td><td align="center" valign="top" rowspan="1" colspan="1">28</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Lammers, 2022</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1">Improving</td><td align="center" valign="top" rowspan="1" colspan="1">10/9</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" rowspan="3" valign="top" colspan="1">fMRI</td><td align="center" rowspan="3" valign="top" colspan="1">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">MMSE ≥ 23</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Stable</td><td align="center" valign="top" rowspan="1" colspan="1">25/52</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Progressing</td><td align="center" valign="top" rowspan="1" colspan="1">10/14</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Li, 2021</td><td align="center" rowspan="2" valign="top" colspan="1">Case–control</td><td align="center" rowspan="2" valign="top" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">Nonfrail (≥ 8)</td><td align="center" valign="top" rowspan="1" colspan="1">7/15</td><td align="center" valign="top" rowspan="1" colspan="1">75.0 ± 6.2</td><td align="center" valign="top" rowspan="1" colspan="1">24.6 ± 5.3</td><td align="center" rowspan="2" valign="top" colspan="1">MRI</td><td align="center" rowspan="2" valign="top" colspan="1">EFS</td><td align="center" rowspan="2" valign="top" colspan="1">MMSE &gt; 15</td><td align="center" rowspan="2" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (&lt; 8)</td><td align="center" valign="top" rowspan="1" colspan="1">12/6</td><td align="center" valign="top" rowspan="1" colspan="1">77.9 ± 4.3</td><td align="center" valign="top" rowspan="1" colspan="1">20.8 ± 4.7</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Maltais, 2019</td><td align="center" rowspan="3" valign="top" colspan="1">Case–control</td><td align="center" rowspan="3" valign="top" colspan="1">France</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" rowspan="3" valign="top" colspan="1">71/42</td><td align="center" rowspan="3" valign="top" colspan="1">74.9 ± 4.1</td><td align="center" rowspan="3" valign="top" colspan="1">—</td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">Dementia excluded</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maltais, 2019</td><td align="center" valign="top" rowspan="1" colspan="1">Cohort</td><td align="center" valign="top" rowspan="1" colspan="1">France</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">162/269</td><td align="center" valign="top" rowspan="1" colspan="1">74.7 ± 4.3</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">PET</td><td align="center" valign="top" rowspan="1" colspan="1">Frailty index</td><td align="center" valign="top" rowspan="1" colspan="1">CDR &lt; 1</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Maltais, 2020</td><td align="center" rowspan="3" valign="top" colspan="1">Case–control</td><td align="center" rowspan="3" valign="top" colspan="1">France</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" rowspan="3" valign="top" colspan="1">136/91</td><td align="center" rowspan="3" valign="top" colspan="1">74.7 ± 3.9</td><td align="center" rowspan="3" valign="top" colspan="1">28.1 ± 1.5</td><td align="center" rowspan="3" valign="top" colspan="1">DTI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">Dementia excluded</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Siejka, 2020</td><td align="center" rowspan="2" valign="top" colspan="1">Cohort</td><td align="center" rowspan="2" valign="top" colspan="1">Australia</td><td align="center" valign="top" rowspan="1" colspan="1">Lower frailty</td><td align="center" valign="top" rowspan="1" colspan="1">85/108</td><td align="center" valign="top" rowspan="1" colspan="1">69.5 ± 6</td><td align="center" rowspan="2" valign="top" colspan="1">—</td><td align="center" rowspan="2" valign="top" colspan="1">MRI</td><td align="center" rowspan="2" valign="top" colspan="1">Rockwood and Mitnitski frailty index</td><td align="center" rowspan="2" valign="top" colspan="1">Dementia excluded</td><td align="center" rowspan="2" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Higher frailty</td><td align="center" valign="top" rowspan="1" colspan="1">87/108</td><td align="center" valign="top" rowspan="1" colspan="1">74.5 ± 7.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Siejka, 2017</td><td align="center" valign="top" rowspan="1" colspan="1">Cohort</td><td align="center" valign="top" rowspan="1" colspan="1">Australia</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">172/216</td><td align="center" valign="top" rowspan="1" colspan="1">72.0 ± 7.0</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">MRI</td><td align="center" valign="top" rowspan="1" colspan="1">Cumulative deficit model of frailty index</td><td align="center" valign="top" rowspan="1" colspan="1">Dementia excluded</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sourdet, 2021</td><td align="center" valign="top" rowspan="1" colspan="1">Cohort</td><td align="center" valign="top" rowspan="1" colspan="1">France</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Amyloid PET, MRI</td><td align="center" valign="top" rowspan="1" colspan="1">Fried criteria</td><td align="center" valign="top" rowspan="1" colspan="1">MMSE &gt; 20</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Suárez‐Méndez, 2021</td><td align="center" rowspan="2" valign="top" colspan="1">Cohort</td><td align="center" rowspan="2" valign="top" colspan="1">Spain</td><td align="center" valign="top" rowspan="1" colspan="1">Robust</td><td align="center" valign="top" rowspan="1" colspan="1">21/13</td><td align="center" valign="top" rowspan="1" colspan="1">78.50</td><td align="center" valign="top" rowspan="1" colspan="1">27.00</td><td align="center" rowspan="2" valign="top" colspan="1">MEG, MRI</td><td align="center" rowspan="2" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="2" valign="top" colspan="1">MMSE ≥ 24</td><td align="center" rowspan="2" valign="top" colspan="1">Age and gender</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail</td><td align="center" valign="top" rowspan="1" colspan="1">15/5</td><td align="center" valign="top" rowspan="1" colspan="1">81.00</td><td align="center" valign="top" rowspan="1" colspan="1">26.00</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Sugimoto, 2019</td><td align="center" rowspan="2" valign="top" colspan="1">Case–control</td><td align="center" rowspan="2" valign="top" colspan="1">Japan</td><td align="center" valign="top" rowspan="1" colspan="1">Healthy older adults</td><td align="center" valign="top" rowspan="1" colspan="1">120/77</td><td align="center" valign="top" rowspan="1" colspan="1">75.5 ± 5.6</td><td align="center" valign="top" rowspan="1" colspan="1">28.2 ± 2.1</td><td align="center" rowspan="2" valign="top" colspan="1">MRI</td><td align="center" rowspan="2" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="2" valign="top" colspan="1">Alzheimer disease ruled out based on criteria of the National Institute on Aging‐Alzheimer's Association (NIA/AA)</td><td align="center" rowspan="2" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">With CF</td><td align="center" valign="top" rowspan="1" colspan="1">86/50</td><td align="center" valign="top" rowspan="1" colspan="1">73.4 ± 5.2</td><td align="center" valign="top" rowspan="1" colspan="1">25.3 ± 2.5</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Tian, 2020</td><td align="center" rowspan="3" valign="top" colspan="1">Case–control</td><td align="center" rowspan="3" valign="top" colspan="1">United States</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">185/177</td><td align="center" valign="top" rowspan="1" colspan="1">70.2 ± 6.9</td><td align="center" rowspan="3" valign="top" colspan="1">—</td><td align="center" rowspan="3" valign="top" colspan="1">DTI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1"><p>MCI excluded based on Peterson criteria</p><p>Dementia excluded based on DSM‐III‐R</p><p>Alzheimer disease excluded based on NINCDS‐ADRDA criteria</p></td><td align="center" rowspan="3" valign="top" colspan="1">Age</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">168/111</td><td align="center" valign="top" rowspan="1" colspan="1">77.2 ± 7.8</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">21/8</td><td align="center" valign="top" rowspan="1" colspan="1">81.3 ± 8.0</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Nishita, 2019</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Japan</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">137/192</td><td align="center" valign="top" rowspan="1" colspan="1">72.7 ± 5.1</td><td align="center" rowspan="3" valign="top" colspan="1">—</td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">Dementia excluded</td><td align="center" rowspan="3" valign="top" colspan="1">Age and sex</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">224/204</td><td align="center" valign="top" rowspan="1" colspan="1">74.6 ± 5.8</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">54/24</td><td align="center" valign="top" rowspan="1" colspan="1">79.2 ± 6.3</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Zhao, 2021</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">206/161</td><td align="center" valign="top" rowspan="1" colspan="1">64.3 ± 5.9</td><td align="center" rowspan="3" valign="top" colspan="1">—</td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">Alzheimer disease excluded</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">199/111</td><td align="center" valign="top" rowspan="1" colspan="1">66.5 ± 6.9</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">29/20</td><td align="center" valign="top" rowspan="1" colspan="1">68.3 ± 6.2</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Isernia, 2023</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Italy</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (0)</td><td align="center" valign="top" rowspan="1" colspan="1">17/17</td><td align="center" valign="top" rowspan="1" colspan="1">71.5, 6.75<xref rid="jcsm13719-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">27.0, 3.5<xref rid="jcsm13719-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" rowspan="3" valign="top" colspan="1">MRI</td><td align="center" rowspan="3" valign="top" colspan="1">Fried criteria</td><td align="center" rowspan="3" valign="top" colspan="1">Severe dementia excluded</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (1–2)</td><td align="center" valign="top" rowspan="1" colspan="1">27/18</td><td align="center" valign="top" rowspan="1" colspan="1">75.0, 10.0<xref rid="jcsm13719-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">26.0, 3.0<xref rid="jcsm13719-note-0003" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (≥ 3)</td><td align="center" valign="top" rowspan="1" colspan="1">14/3</td><td align="center" valign="top" rowspan="1" colspan="1">78.0, 11.0<xref rid="jcsm13719-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1">25.7, 3.9<xref rid="jcsm13719-note-0003" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Gutiérrez‐Zúñiga, 2023</td><td align="center" rowspan="3" valign="top" colspan="1">Cohort</td><td align="center" rowspan="3" valign="top" colspan="1">Ireland</td><td align="center" valign="top" rowspan="1" colspan="1">Robust (FI &lt; 0.10)</td><td align="center" valign="top" rowspan="1" colspan="1">143/152</td><td align="center" valign="top" rowspan="1" colspan="1">66.9 ± 7.0</td><td align="center" rowspan="3" valign="top" colspan="1">—</td><td align="center" rowspan="3" valign="top" colspan="1">MRI, DTI</td><td align="center" rowspan="3" valign="top" colspan="1">A self‐reported 32‐item FI</td><td align="center" rowspan="3" valign="top" colspan="1">Neurodegenerative diseases excluded</td><td align="center" rowspan="3" valign="top" colspan="1">—</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Prefrail (FI 0.10–0.24)</td><td align="center" valign="top" rowspan="1" colspan="1">103/87</td><td align="center" valign="top" rowspan="1" colspan="1">70.7 ± 7.0</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Frail (FI ≥ 0.25)</td><td align="center" valign="top" rowspan="1" colspan="1">23/15</td><td align="center" valign="top" rowspan="1" colspan="1">74.3 ± 6.9</td></tr></tbody></table><table-wrap-foot id="jcsm13719-ntgp-0002"><fn id="jcsm13719-note-0002"><p>Abbreviations: CDR, Clinical Dementia Rating scale; CHS, Cardiovascular Health Study frailty score; CN, cognitively normal; DSM‐III‐R, Diagnostic and Statistical Manual, third edition revised; DTI, diffusion tensor imaging; EFS, Edmonton frailty scale; fMRI, functional magnetic resonance imaging; IST, Isaacs Set Test; MCI, mildly cognitively impaired; MEG, magnetoencephalography; MMSE, Mini‐Mental State Examination; MRI, magnetic resonance imaging; NINCDS‐ADRDA, National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association; PET, positron emission tomography.</p></fn><fn id="jcsm13719-note-0003"><label><sup>a</sup></label><p>Median, IQR.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>TABLE 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Characteristics of included studies.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom">Study</th><th align="center" valign="bottom">Study design</th><th align="center" valign="bottom">Country</th><th align="center" valign="bottom">Study groups (frailty score)</th><th align="center" valign="bottom">Sample size F/M</th><th align="center" valign="bottom">Age (years) mean ± SD</th><th align="center" valign="bottom">Mean MMSE ± SD</th><th align="center" valign="bottom">Modality</th><th align="center" valign="bottom">Frailty measurements</th><th align="center" valign="bottom">Cognitive status</th><th align="center" valign="bottom">Matched for</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top">Avila‐Funes, 2016</td><td align="center" rowspan="2" valign="top">Cohort</td><td align="center" rowspan="2" valign="top">Mexico</td><td align="center" valign="top">Robust</td><td align="center" valign="top">51/92</td><td align="center" valign="top">75.0 ± 5.0</td><td align="center" valign="top">27.2 ± 2.1</td><td align="center" rowspan="2" valign="top">MRI, DTI</td><td align="center" rowspan="2" valign="top">Fried criteria</td><td align="center" rowspan="2" valign="top">MMSE &gt; 15</td><td align="center" rowspan="2" valign="top">—</td></tr><tr><td align="center" valign="top">Frail</td><td align="center" valign="top">19/14</td><td align="center" valign="top">76.0 ± 5.7</td><td align="center" valign="top">26.4 ± 2.7</td></tr><tr><td rowspan="3" align="left" valign="top">Chen, 2015</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Taiwan</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">119/140</td><td align="center" valign="top">62.5 ± 7.7</td><td align="center" valign="top">26.9 ± 2.9</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Fried criteria</td><td align="center" rowspan="3" valign="top">Dementia excluded based on MMSE score</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">89/89</td><td align="center" valign="top">65.2 ± 9.0</td><td align="center" valign="top">25.8 ± 3.4</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">9/10</td><td align="center" valign="top">73.6 ± 7.4</td><td align="center" valign="top">23.1 ± 3.8</td></tr><tr><td rowspan="3" align="left" valign="top">Chung, 2016</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Taiwan</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">348/263</td><td align="center" valign="top">60.34 ± 7.28</td><td align="center" rowspan="3" valign="top">—</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Fried criteria, CHS score</td><td align="center" rowspan="3" valign="top">Score &gt; 24 in well‐educated subjectsMMSE score &gt; 14 in less‐educated subjects</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">173/146</td><td align="center" valign="top">65.28 ± 9.00</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">16/16</td><td align="center" valign="top">74.90 ± 7.86</td></tr><tr><td rowspan="2" align="left" valign="top">Ducca, 2022</td><td align="center" rowspan="2" valign="top">Cohort</td><td align="center" rowspan="2" valign="top">United States</td><td align="center" valign="top">Robust (&lt; 3)</td><td align="center" valign="top">954/671</td><td align="center" valign="top">76.0 ± 4.7</td><td align="center" rowspan="2" valign="top">—</td><td align="center" rowspan="2" valign="top">MRI, DTI</td><td align="center" rowspan="2" valign="top">Fried criteria</td><td align="center" rowspan="2" valign="top">Participants who did not meet criteria for MCI or dementia according to expert adjudications</td><td align="center" rowspan="2" valign="top">—</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">87/42</td><td align="center" valign="top">78.5 ± 5.5</td></tr><tr><td rowspan="3" align="left" valign="top">Kant, 2019</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Netherlands</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">12/43</td><td align="center" valign="top">70 ± 4</td><td align="center" valign="top">29</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Fried criteria</td><td align="center" rowspan="3" valign="top">MMSE &gt; 24</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">24/61</td><td align="center" valign="top">72 ± 5</td><td align="center" valign="top">29</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">16/14</td><td align="center" valign="top">74 ± 5</td><td align="center" valign="top">28</td></tr><tr><td rowspan="2" align="left" valign="top">Suárez‐Méndez, 2020</td><td align="center" rowspan="2" valign="top">Case–control</td><td align="center" rowspan="2" valign="top">Spain</td><td align="center" valign="top">Robust</td><td align="center" valign="top">21/13</td><td align="center" valign="top">78.50</td><td align="center" valign="top">27.0</td><td align="center" rowspan="2" valign="top">MEG, MRI</td><td align="center" rowspan="2" valign="top">Fried criteria</td><td align="center" rowspan="2" valign="top">MMSE &gt; 24</td><td align="center" rowspan="2" valign="top">Age and gender</td></tr><tr><td align="center" valign="top">Frail</td><td align="center" valign="top">15/5</td><td align="center" valign="top">81</td><td align="center" valign="top">26.0</td></tr><tr><td rowspan="3" align="left" valign="top">Kant, 2018</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Netherlands</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">24/51</td><td align="center" valign="top">71.6 ± 4.5</td><td align="center" valign="top">29</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top">MMSE &gt; 24</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">37/70</td><td align="center" valign="top">72.3 ± 5.0</td><td align="center" valign="top">29</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">19/13</td><td align="center" valign="top">74.7 ± 5.4</td><td align="center" valign="top">28</td></tr><tr><td rowspan="3" align="left" valign="top">Lammers, 2020</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Germany</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">19/41</td><td align="center" valign="top">70.5</td><td align="center" valign="top">29</td><td align="center" rowspan="3" valign="top">fMRI</td><td align="center" rowspan="3" valign="top">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top">MMSE &gt; 24</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">37/33</td><td align="center" valign="top">71.5</td><td align="center" valign="top">29</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">8/5</td><td align="center" valign="top">74.0</td><td align="center" valign="top">28</td></tr><tr><td rowspan="3" align="left" valign="top">Lammers, 2022</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Germany</td><td align="center" valign="top">Improving</td><td align="center" valign="top">10/9</td><td align="center" valign="top">73</td><td align="center" valign="top">28</td><td align="center" rowspan="3" valign="top">fMRI</td><td align="center" rowspan="3" valign="top">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top">MMSE ≥ 23</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Stable</td><td align="center" valign="top">25/52</td><td align="center" valign="top">71</td><td align="center" valign="top">29</td></tr><tr><td align="center" valign="top">Progressing</td><td align="center" valign="top">10/14</td><td align="center" valign="top">71</td><td align="center" valign="top">29</td></tr><tr><td rowspan="2" align="left" valign="top">Li, 2021</td><td align="center" rowspan="2" valign="top">Case–control</td><td align="center" rowspan="2" valign="top">China</td><td align="center" valign="top">Nonfrail (≥ 8)</td><td align="center" valign="top">7/15</td><td align="center" valign="top">75.0 ± 6.2</td><td align="center" valign="top">24.6 ± 5.3</td><td align="center" rowspan="2" valign="top">MRI</td><td align="center" rowspan="2" valign="top">EFS</td><td align="center" rowspan="2" valign="top">MMSE &gt; 15</td><td align="center" rowspan="2" valign="top">—</td></tr><tr><td align="center" valign="top">Frail (&lt; 8)</td><td align="center" valign="top">12/6</td><td align="center" valign="top">77.9 ± 4.3</td><td align="center" valign="top">20.8 ± 4.7</td></tr><tr><td rowspan="3" align="left" valign="top">Maltais, 2019</td><td align="center" rowspan="3" valign="top">Case–control</td><td align="center" rowspan="3" valign="top">France</td><td align="center" valign="top">Robust (0)</td><td align="center" rowspan="3" valign="top">71/42</td><td align="center" rowspan="3" valign="top">74.9 ± 4.1</td><td align="center" rowspan="3" valign="top">—</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Fried criteria</td><td align="center" rowspan="3" valign="top">Dementia excluded</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td></tr><tr><td align="left" valign="top">Maltais, 2019</td><td align="center" valign="top">Cohort</td><td align="center" valign="top">France</td><td align="center" valign="top">—</td><td align="center" valign="top">162/269</td><td align="center" valign="top">74.7 ± 4.3</td><td align="center" valign="top">—</td><td align="center" valign="top">PET</td><td align="center" valign="top">Frailty index</td><td align="center" valign="top">CDR &lt; 1</td><td align="center" valign="top">—</td></tr><tr><td rowspan="3" align="left" valign="top">Maltais, 2020</td><td align="center" rowspan="3" valign="top">Case–control</td><td align="center" rowspan="3" valign="top">France</td><td align="center" valign="top">Robust (0)</td><td align="center" rowspan="3" valign="top">136/91</td><td align="center" rowspan="3" valign="top">74.7 ± 3.9</td><td align="center" rowspan="3" valign="top">28.1 ± 1.5</td><td align="center" rowspan="3" valign="top">DTI</td><td align="center" rowspan="3" valign="top">Fried criteria</td><td align="center" rowspan="3" valign="top">Dementia excluded</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td></tr><tr><td rowspan="2" align="left" valign="top">Siejka, 2020</td><td align="center" rowspan="2" valign="top">Cohort</td><td align="center" rowspan="2" valign="top">Australia</td><td align="center" valign="top">Lower frailty</td><td align="center" valign="top">85/108</td><td align="center" valign="top">69.5 ± 6</td><td align="center" rowspan="2" valign="top">—</td><td align="center" rowspan="2" valign="top">MRI</td><td align="center" rowspan="2" valign="top">Rockwood and Mitnitski frailty index</td><td align="center" rowspan="2" valign="top">Dementia excluded</td><td align="center" rowspan="2" valign="top">—</td></tr><tr><td align="center" valign="top">Higher frailty</td><td align="center" valign="top">87/108</td><td align="center" valign="top">74.5 ± 7.1</td></tr><tr><td align="left" valign="top">Siejka, 2017</td><td align="center" valign="top">Cohort</td><td align="center" valign="top">Australia</td><td align="center" valign="top">—</td><td align="center" valign="top">172/216</td><td align="center" valign="top">72.0 ± 7.0</td><td align="center" valign="top">—</td><td align="center" valign="top">MRI</td><td align="center" valign="top">Cumulative deficit model of frailty index</td><td align="center" valign="top">Dementia excluded</td><td align="center" valign="top">—</td></tr><tr><td align="left" valign="top">Sourdet, 2021</td><td align="center" valign="top">Cohort</td><td align="center" valign="top">France</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">Amyloid PET, MRI</td><td align="center" valign="top">Fried criteria</td><td align="center" valign="top">MMSE &gt; 20</td><td align="center" valign="top">—</td></tr><tr><td rowspan="2" align="left" valign="top">Suárez‐Méndez, 2021</td><td align="center" rowspan="2" valign="top">Cohort</td><td align="center" rowspan="2" valign="top">Spain</td><td align="center" valign="top">Robust</td><td align="center" valign="top">21/13</td><td align="center" valign="top">78.50</td><td align="center" valign="top">27.00</td><td align="center" rowspan="2" valign="top">MEG, MRI</td><td align="center" rowspan="2" valign="top">Fried criteria</td><td align="center" rowspan="2" valign="top">MMSE ≥ 24</td><td align="center" rowspan="2" valign="top">Age and gender</td></tr><tr><td align="center" valign="top">Frail</td><td align="center" valign="top">15/5</td><td align="center" valign="top">81.00</td><td align="center" valign="top">26.00</td></tr><tr><td rowspan="2" align="left" valign="top">Sugimoto, 2019</td><td align="center" rowspan="2" valign="top">Case–control</td><td align="center" rowspan="2" valign="top">Japan</td><td align="center" valign="top">Healthy older adults</td><td align="center" valign="top">120/77</td><td align="center" valign="top">75.5 ± 5.6</td><td align="center" valign="top">28.2 ± 2.1</td><td align="center" rowspan="2" valign="top">MRI</td><td align="center" rowspan="2" valign="top">Fried criteria</td><td align="center" rowspan="2" valign="top">Alzheimer disease ruled out based on criteria of the National Institute on Aging‐Alzheimer's Association (NIA/AA)</td><td align="center" rowspan="2" valign="top">—</td></tr><tr><td align="center" valign="top">With CF</td><td align="center" valign="top">86/50</td><td align="center" valign="top">73.4 ± 5.2</td><td align="center" valign="top">25.3 ± 2.5</td></tr><tr><td rowspan="3" align="left" valign="top">Tian, 2020</td><td align="center" rowspan="3" valign="top">Case–control</td><td align="center" rowspan="3" valign="top">United States</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">185/177</td><td align="center" valign="top">70.2 ± 6.9</td><td align="center" rowspan="3" valign="top">—</td><td align="center" rowspan="3" valign="top">DTI</td><td align="center" rowspan="3" valign="top">Fried criteria</td><td align="center" rowspan="3" valign="top">MCI excluded based on Peterson criteriaDementia excluded based on DSM‐III‐RAlzheimer disease excluded based on NINCDS‐ADRDA criteria</td><td align="center" rowspan="3" valign="top">Age</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">168/111</td><td align="center" valign="top">77.2 ± 7.8</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">21/8</td><td align="center" valign="top">81.3 ± 8.0</td></tr><tr><td rowspan="3" align="left" valign="top">Nishita, 2019</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Japan</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">137/192</td><td align="center" valign="top">72.7 ± 5.1</td><td align="center" rowspan="3" valign="top">—</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Modified version of Fried criteria</td><td align="center" rowspan="3" valign="top">Dementia excluded</td><td align="center" rowspan="3" valign="top">Age and sex</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">224/204</td><td align="center" valign="top">74.6 ± 5.8</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">54/24</td><td align="center" valign="top">79.2 ± 6.3</td></tr><tr><td rowspan="3" align="left" valign="top">Zhao, 2021</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">China</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">206/161</td><td align="center" valign="top">64.3 ± 5.9</td><td align="center" rowspan="3" valign="top">—</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Fried criteria</td><td align="center" rowspan="3" valign="top">Alzheimer disease excluded</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">199/111</td><td align="center" valign="top">66.5 ± 6.9</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">29/20</td><td align="center" valign="top">68.3 ± 6.2</td></tr><tr><td rowspan="3" align="left" valign="top">Isernia, 2023</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Italy</td><td align="center" valign="top">Robust (0)</td><td align="center" valign="top">17/17</td><td align="center" valign="top">71.5, 6.75???</td><td align="center" valign="top">27.0, 3.5???</td><td align="center" rowspan="3" valign="top">MRI</td><td align="center" rowspan="3" valign="top">Fried criteria</td><td align="center" rowspan="3" valign="top">Severe dementia excluded</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (1–2)</td><td align="center" valign="top">27/18</td><td align="center" valign="top">75.0, 10.0???</td><td align="center" valign="top">26.0, 3.0???</td></tr><tr><td align="center" valign="top">Frail (≥ 3)</td><td align="center" valign="top">14/3</td><td align="center" valign="top">78.0, 11.0???</td><td align="center" valign="top">25.7, 3.9???</td></tr><tr><td rowspan="3" align="left" valign="top">Gutiérrez‐Zúñiga, 2023</td><td align="center" rowspan="3" valign="top">Cohort</td><td align="center" rowspan="3" valign="top">Ireland</td><td align="center" valign="top">Robust (FI &lt; 0.10)</td><td align="center" valign="top">143/152</td><td align="center" valign="top">66.9 ± 7.0</td><td align="center" rowspan="3" valign="top">—</td><td align="center" rowspan="3" valign="top">MRI, DTI</td><td align="center" rowspan="3" valign="top">A self‐reported 32‐item FI</td><td align="center" rowspan="3" valign="top">Neurodegenerative diseases excluded</td><td align="center" rowspan="3" valign="top">—</td></tr><tr><td align="center" valign="top">Prefrail (FI 0.10–0.24)</td><td align="center" valign="top">103/87</td><td align="center" valign="top">70.7 ± 7.0</td></tr><tr><td align="center" valign="top">Frail (FI ≥ 0.25)</td><td align="center" valign="top">23/15</td><td align="center" valign="top">74.3 ± 6.9</td></tr></tbody></table></div>Abbreviations: CDR, Clinical Dementia Rating scale; CHS, Cardiovascular Health Study frailty score; CN, cognitively normal; DSM‐III‐R, Diagnostic and Statistical Manual, third edition revised; DTI, diffusion tensor imaging; EFS, Edmonton frailty scale; fMRI, functional magnetic resonance imaging; IST, Isaacs Set Test; MCI, mildly cognitively impaired; MEG, magnetoencephalography; MMSE, Mini‐Mental State Examination; MRI, magnetic resonance imaging; NINCDS‐ADRDA, National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association; PET, positron emission tomography.aMedian, IQR.</transformed-table></extracted-table><extracted-table><table-id>jcsm13719-tbl-0002</table-id><table-label>TABLE 2</table-label><table-caption>A summary of findings of studies on MRI.</table-caption><table-wrap-foot>Abbreviations: AF, atrial fibrillation; AG, angular gyrus; BG, basal ganglia; BMI, body mass index; BNP, B‐type natriuretic peptide; BPV, brain parenchymal volume; CF, cognitive frailty; CKD, chronic kidney disease; CMB, cerebral microbleeds; CN, cognitively normal; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; CSF, cerebrospinal fluid; CSFV, cerebral spinal fluid volume; CSVD, cerebral small vessel disease; DAN, dorsal attention network; DM, diabetes mellitus; DWI, diffusion weighted imaging; EFS, Edmonton frailty scale; eGFR, estimated glomerular filtration rate; EPVS, enlarged perivascular spaces; FLAIR, fluid‐attenuated inversion recovery; FPN, frontoparietal network; GMF, grey matter fraction (GMV/BPV); GMV, grey matter volume; GRE, gradient echo sequences; hs‐CRP, high sensitivity C‐reactive protein; ICV, intracranial volume; IFG, inferior frontal gyrus; IHD, ischemic heart disease; MCI, mildly cognitively impaired; MEG, magnetoencephalography; MFG, middle frontal gyrus; MYF, myelin fraction (MYV/BPV); MYV, myelin volume; PAR, parenchyma; PD, proton density; pDMN, posterior default mode network; PF, physical frailty; RH, right hemisphere; SI, subcortical infarct; SMA, sensory motor area; SMG, supramarginal gyrus; SMR, sensorimotor rhythm; SPL, superior parietal lobule; SVD, small vessel disease; SWI, susceptibility weighted imaging; T, tesla; TBV, total brain volume; TIV, total intracranial volume; VAN, ventral attention network; WHV, white matter hyperintensity volume; WM, white matter; WMF, white matter fraction (WMV/BPV); WMH, white matter hyperintensity; WMV, white matter volume.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="jcsm13719-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>A summary of findings of studies on MRI.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">MR field strength and sequence</th><th align="center" valign="bottom" rowspan="1" colspan="1">Measures</th><th align="center" valign="bottom" rowspan="1" colspan="1">Brain areas</th><th align="center" valign="bottom" rowspan="1" colspan="1">Covariates</th><th align="center" valign="bottom" rowspan="1" colspan="1">White matter alterations</th><th align="center" valign="bottom" rowspan="1" colspan="1">Grey matter alterations</th><th align="center" valign="bottom" rowspan="1" colspan="1">CSF alteration</th><th align="center" valign="bottom" rowspan="1" colspan="1">Whole brain alterations</th><th align="center" valign="bottom" rowspan="1" colspan="1">Other correlations</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Avila‐Funes, 2016</td><td align="center" valign="top" rowspan="1" colspan="1">1.5 T FLAIR, T1</td><td align="center" valign="top" rowspan="1" colspan="1"><styled-content style="color:#FF0000">WHV</styled-content></td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, educational level, myocardial infarction, angina pectoris, stroke or hypercholesterolaemia, hypertension, diabetes, smoking status, cognitive status</td><td align="center" valign="top" rowspan="1" colspan="1">Higher <styled-content style="color:#FF0000">WHV</styled-content> in frail older adults compared with nonfrails</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chen, 2015</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1, T2‐FLAIR</td><td align="center" valign="top" rowspan="1" colspan="1">GMV, WMV, CSF volume, WMH, TIV</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, Charlson comorbidity index, cognitive function, mood and depressive symptoms, educational years, BMI, blood cell count and biochemistry (fasting blood sugar, total hypercholesterolaemia, albumin, total protein, uric acid, serum creatinine, Hs‐CRP, urine analysis and dual‐energy X‐ray absorptiometry)</td><td align="center" valign="top" rowspan="1" colspan="1">No difference in WMH quantification and WM volume</td><td align="center" valign="top" rowspan="1" colspan="1"><p>No difference in GMV</p><p>At‐risk group showed reduced GMV, compared to the robust group, in 13 brain regions including the cerebellum, hippocampi, middle frontal gyri, right inferior parietal lobule, precentral gyrus, left insula, anterior cingulate and middle occipital gyrus</p></td><td align="center" valign="top" rowspan="1" colspan="1">Higher CSF volume in the at‐risk (prefrail and frail) subjects compared with the robust group</td><td align="center" valign="top" rowspan="1" colspan="1">No difference in TIV volume</td><td align="center" valign="top" rowspan="1" colspan="1">Slowness, weakness and low activity involved reduced GMV in the cerebellum. Weight loss was associated with both GMV reduction (the right postcentral gyrus) and increase (the right posterior cingulate) topographically different from frailty‐related regions</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chunga, 2016</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T2‐FLAIR</td><td align="center" valign="top" rowspan="1" colspan="1">CMB, number of lacune, WMH</td><td align="center" valign="top" rowspan="1" colspan="1"><p>‐ Deep (basal ganglia, thalamus, internal capsule, external capsule, corpus callosum and deep/periventricular white matter), lobar (fontal, parietal, temporal and occipital regions)</p><p>‐ Infratentorial categories (brainstem and cerebellum)</p></td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, educational levels, smoking status, coronary artery disease, CKD, hypertension, DM, hyperlipidaemia, height, weight, BMI, cognitive function, mood and depressive symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Both number and topography of CMB were associated with physical frail status, independent of age and vascular risk factors. The incidence and number of CMBs in the deep or infratentorial regions were associated with the severity of physical frailty. CMBs located in the lobar regions, either mixed with deep/infratentorial or strictly lobar CMB, were not associated with the severity of the physically frail status. The number of lacunes was significantly associated with the severity of the physical frail status. CMB located in the brainstem was significantly associated with physical frailty. The presence of CMBs in the brainstem was significantly associated with the severity of physical frailty; the presence of CMB in the brainstem was revealed as an independent factor associated with the presence of weakness</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ducca, 2022</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T2, FLAIR</td><td align="center" valign="top" rowspan="1" colspan="1"><styled-content style="color:#FF0000">WHV</styled-content></td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, race, educational levels, hypertension, coronary artery disease, diabetes, current smoking, stroke, cognitive status, BMI, APOEe4 status</td><td align="center" valign="top" rowspan="1" colspan="1">Individuals with physical frailty have greater <styled-content style="color:#FF0000">WHV</styled-content> and white matter microstructural abnormalities than nonfrails. This relationship was observed in participants without a history of stroke or dementia but did not persist when analyses were restricted to cognitively normal individuals, that is, the group of participants without MCI or dementia. <styled-content style="color:#FF0000">WHV</styled-content> was significantly associated with new‐onset frailty over a 7‐year follow‐up period, even among cognitively normal adults. These results were consistent in Black and White participants and in men and women. Unlike <styled-content style="color:#FF0000">WHV</styled-content>, general measures of white matter microstructural integrity were not associated with the risk of future frailty. However, secondary analyses did find that the microstructural integrity of specific white matter tracts was associated with future frailty</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kant, 2019</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1, FLAIR, DWI</td><td align="center" valign="top" rowspan="1" colspan="1"><styled-content style="color:#FF0000">WHV</styled-content>, WMH shape, lacunar infarcts</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, hypertension, cognitive status, depressive symptoms, diabetes, BMI, obesity, smoking status, stroke, American Society of Anaesthesiologists score</td><td align="center" valign="top" rowspan="1" colspan="1">Frail and prefrail participants had a higher <styled-content style="color:#FF0000">WHV</styled-content> compared to nonfrail participants. Prefrail participants showed a more complex shape of periventricular and confluent WMH compared to nonfrail participants</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">No between‐group differences were found in shape features of deep WMH, cerebral perfusion or presence of lacunar infarct</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kant, 2018</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1, FLAIR</td><td align="center" valign="top" rowspan="1" colspan="1">TBV, GMV, <styled-content style="color:#FF0000">WHV</styled-content>, WM volume, presence of a cortical brain infarct</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, gender, BMI, DM, smoking status, hypertension, hypercholesterolaemia, cognitive status, American Society of Anaesthesiologists score</td><td align="center" valign="top" rowspan="1" colspan="1">Higher <styled-content style="color:#FF0000">WHV</styled-content> in frail individuals</td><td align="center" valign="top" rowspan="1" colspan="1">Lower GMV in frail individuals</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Lower TBV in frail individuals; frail individuals showed a lower global cortical thickness compared to prefrail and nonfrail individuals; however, no regional clusters of a lower cortical thickness were found</td><td align="center" valign="top" rowspan="1" colspan="1">More cortical infarcts in frail individuals; individual frailty components showed a relation with a lower global grey matter volume, but this did not reach statistical significance. Furthermore, prefrail individuals had more cortical brain infarcts compared to nonfrail individuals</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Li, 2021</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1, T2, DWI</td><td align="center" valign="top" rowspan="1" colspan="1">GMV, WMV, CSFV, MYV, BPV, ICV, GMF, WMF, MYF, GMV/ICV, WMV/ICV, CSF/ICV, MYV/ICV</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, BMI, educational level, cognitive status</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple regional GM volumetry showed significant correlations with the EFS. No significant correlation was found between the EFS and regional GM relaxometry. Both global volumetry and global relaxometry showed strong correlations with some domain scores of the EFS. Some regional GM volumetry showed strong negative correlations with the functional performance score. Significant negative correlations were identified between the functional performance score and the GMV of Rolandic, olfactory, rectus, cingulate, hippocampus, parahippocampal and precuneus. No notable correlations were found between regional GMV and the cognition score, general health status score, functional independence score, medication use score, nutrition score, mood score or continence score. Significant negative correlations were found between the functional independence score and the T1 value of caudate. No notable correlations were identified between the other scores and regional GM T1 values. Significant negative correlations were identified between the functional independence score and the T2 values of insula and caudate. No notable correlations were found between the other scores and regional GM T2 values. No significant correlations between the domain scores of the EFS and regional GM PD values were identified</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maltais, 2019</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1"><styled-content style="color:#FF0000">WHV</styled-content>, WMH progression</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, educational level, DM, hypertension, hypercholesterolaemia</td><td align="center" valign="top" rowspan="1" colspan="1">A significant increase in likelihood of increasing 1 point on the frailty phenotype score over 3 years with higher baseline WMH. For the progression of WMH, no significant associations were found for the continuous variable as well as the dichotomous variable (fast vs. slow progression of WMH) with frailty evolution</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Siejka, 2020</td><td align="center" valign="top" rowspan="1" colspan="1">1.5 T T1, T2, FLAIR, GRE</td><td align="center" valign="top" rowspan="1" colspan="1">WMH, SI, microbleeds</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, educational level</td><td align="center" valign="top" rowspan="1" colspan="1">Higher baseline WMH was associated with a greater progression in frailty. WMH was significantly associated with progressively worsening frailty. A higher burden of baseline WMH was more strongly associated with progression of frailty</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">SI and microbleeds were not significantly associated with progression of frailty</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Siejka, 2017</td><td align="center" valign="top" rowspan="1" colspan="1">1.5 T T1, T2, FLAIR, GRE</td><td align="center" valign="top" rowspan="1" colspan="1">WMH, SI, CMB</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, educational level</td><td align="center" valign="top" rowspan="1" colspan="1">WMH in unadjusted models was positively associated with higher frailty scores. In final models including all brain variables, higher burden of WMH was independently associated with a higher frailty score. In fully adjusted models, WMH was associated with the motor index</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">SI and CMB in unadjusted models were positively associated with higher frailty scores. In final models including all brain variables, higher burden of SI or CMB was not associated with a higher frailty score</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Suárez‐Méndez, 2021</td><td align="center" valign="top" rowspan="1" colspan="1">0.23 T T1</td><td align="center" valign="top" rowspan="1" colspan="1">MEG</td><td align="center" valign="top" rowspan="1" colspan="1">Whole brain</td><td align="center" valign="top" rowspan="1" colspan="1">Age, gender, hypertension, DM, dyslipidaemia, COPD/asthma, presence of osteoporosis, vertebral fracture, low Vitamin D, AF, IHD, cancer, incontinence, functional status, neuropsychological status</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1"><p>Significant group differences in relative power were found in the classical alpha (mu) and SMR frequency bands. We found no significant group differences in theta nor beta frequencies after multiple comparison correction found in the RH affecting posterior parietal areas (e.g., AG and SPL), the primary somatosensory cortex and the superior occipital cortex. Significant bilateral differences involved areas of the primary motor cortex. These regions comprise those classically associated with traditional generators of mu activity; thus henceforth, we will refer to our results within this range as mu oscillations</p><p>Significant group differences were found in SMR relative power after multiple comparison correction. Frail participants exhibited increased SMR relative power in comparison to their robust peers. The strongest differences were found in frontal areas of the RH, including the premotor cortex, the supplementary motor area and the paracingulate gyrus</p></td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sugimoto, 2019</td><td align="center" valign="top" rowspan="1" colspan="1">1.5 T T1, T2, FLAIR</td><td align="center" valign="top" rowspan="1" colspan="1">ICV, WMH, parenchyma volume, WMH/PAR</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, BMI, educational level, cognitive function, functional status, smoking status, drinking status, hypertension, DM, hyperlipidaemia, coronary artery disease, CRP, BNP, homocysteine, eGFR</td><td align="center" valign="top" rowspan="1" colspan="1">Higher WMH and WMH/PAR volumes in CF individuals. WMH/PAR volume was shown to be highest among those with minimal cognitive impairment and PF. The PF/CN, pre‐PF/MCI and PF/MCI groups had significantly higher WMH/PAR volumes compared to the non‐PF/CN group. PF subjects had higher WMH volumes compared to non‐PF subjects among patients without MCI</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Lower IC and PAR volumes in CF individuals</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nishita, 2019</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1</td><td align="center" valign="top" rowspan="1" colspan="1">GMV</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, education level, marital status, conditions of habitation (living alone, living with others), employment (employed, unemployed), current smoking status, hypertension, stroke, heart disease, DM, dyslipidaemia, presence of osteoporosis, chronic bronchitis and knee arthropathy</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Volumes of GM of each region did not differ significantly among physically frail, prefrail and robust groups</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Weakness and slowness were significantly and negatively associated with the grey matter volumes of specific regions. Weakness was significantly associated with reduced GMV in the right anterior hippocampal and amygdala clusters and the bilateral fusiform gyrus. Regions significantly associated with slowness overlapped with regions significantly associated with weakness: the bilateral anterior hippocampus and amygdala and fusiform gyrus. Slowness was associated with a reduced volume of more extensive brain regions, including the bilateral medial prefrontal and orbitofrontal cortex, inferior frontal gyrus, primary somatosensory cortex, insula, superior temporal sulcus and cerebellum</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zhao, 2021</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1, T2, FLAIR, DWI, SWI</td><td align="center" valign="top" rowspan="1" colspan="1">WMH, lacunes, CMB, EPVS‐BG</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, weight, education level, smoking, and alcohol drinking status, hypertension, stroke, coronary heart disease, DM, hyperlipidaemia, kidney disease, arthritis, migraine, depressive symptoms, sleep quality</td><td align="center" valign="top" rowspan="1" colspan="1">The severity of the WMH was correlated with frailty and sleep quality</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Participants with a higher CSVD burden were more likely to be frail. The severity of the EPVS‐BG and the number of lacunes were correlated with frailty and sleep quality. Sleep quality played a partial mediating role in the association between CSVD burden and physical frailty</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Isernia, 2023</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1‐3D, FLAIR, T2</td><td align="center" valign="top" rowspan="1" colspan="1">Brain morphometry, WMH</td><td align="center" valign="top" rowspan="1" colspan="1">Whole brain</td><td align="center" valign="top" rowspan="1" colspan="1">Sex, age, education level, memory, attention, language</td><td align="center" valign="top" rowspan="1" colspan="1">No notable associations between the frailty score and the overall volume of WMH</td><td align="center" valign="top" rowspan="1" colspan="1">Frailty was shown to be correlated with decreased cortical thickness in the left supramarginal gyrus and the right rostral middle frontal gyrus</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">No notable associations between the frailty score and the volumes of subcortical areas</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gutiérrez‐Zúñiga, 2023</td><td align="center" valign="top" rowspan="1" colspan="1">3 T T1‐3D, DTI</td><td align="center" valign="top" rowspan="1" colspan="1">Grey matter measures (cortical and subcortical) and white matter tracts</td><td align="center" valign="top" rowspan="1" colspan="1">Cortex, basal ganglia and each of the Desikan–Killiany regional volumes</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, medical history (number of regular medications, vascular diseases, cancer and smoking history), physical exercise in metabolic equivalents and quality of life measured by the CASP‐12 scale</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">The FI exhibited a negative correlation with the total volume of the cortex</td><td align="center" valign="top" rowspan="1" colspan="1">The basal ganglia measurements showed a negative correlation between thalamic volumes and the FI</td></tr></tbody></table><table-wrap-foot id="jcsm13719-ntgp-0003"><fn id="jcsm13719-note-0004"><p>Abbreviations: AF, atrial fibrillation; AG, angular gyrus; BG, basal ganglia; BMI, body mass index; BNP, B‐type natriuretic peptide; BPV, brain parenchymal volume; CF, cognitive frailty; CKD, chronic kidney disease; CMB, cerebral microbleeds; CN, cognitively normal; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; CSF, cerebrospinal fluid; CSFV, cerebral spinal fluid volume; CSVD, cerebral small vessel disease; DAN, dorsal attention network; DM, diabetes mellitus; DWI, diffusion weighted imaging; EFS, Edmonton frailty scale; eGFR, estimated glomerular filtration rate; EPVS, enlarged perivascular spaces; FLAIR, fluid‐attenuated inversion recovery; FPN, frontoparietal network; GMF, grey matter fraction (GMV/BPV); GMV, grey matter volume; GRE, gradient echo sequences; hs‐CRP, high sensitivity C‐reactive protein; ICV, intracranial volume; IFG, inferior frontal gyrus; IHD, ischemic heart disease; MCI, mildly cognitively impaired; MEG, magnetoencephalography; MFG, middle frontal gyrus; MYF, myelin fraction (MYV/BPV); MYV, myelin volume; PAR, parenchyma; PD, proton density; pDMN, posterior default mode network; PF, physical frailty; RH, right hemisphere; SI, subcortical infarct; SMA, sensory motor area; SMG, supramarginal gyrus; SMR, sensorimotor rhythm; SPL, superior parietal lobule; SVD, small vessel disease; SWI, susceptibility weighted imaging; T, tesla; TBV, total brain volume; TIV, total intracranial volume; VAN, ventral attention network; WHV, white matter hyperintensity volume; WM, white matter; WMF, white matter fraction (WMV/BPV); WMH, white matter hyperintensity; WMV, white matter volume.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>TABLE 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">A summary of findings of studies on MRI.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom">Study</th><th align="center" valign="bottom">MR field strength and sequence</th><th align="center" valign="bottom">Measures</th><th align="center" valign="bottom">Brain areas</th><th align="center" valign="bottom">Covariates</th><th align="center" valign="bottom">White matter alterations</th><th align="center" valign="bottom">Grey matter alterations</th><th align="center" valign="bottom">CSF alteration</th><th align="center" valign="bottom">Whole brain alterations</th><th align="center" valign="bottom">Other correlations</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top">Avila‐Funes, 2016</td><td align="center" valign="top">1.5 T FLAIR, T1</td><td align="center" valign="top">WHV</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, educational level, myocardial infarction, angina pectoris, stroke or hypercholesterolaemia, hypertension, diabetes, smoking status, cognitive status</td><td align="center" valign="top">Higher WHV in frail older adults compared with nonfrails</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td></tr><tr><td align="left" valign="top">Chen, 2015</td><td align="center" valign="top">3 T T1, T2‐FLAIR</td><td align="center" valign="top">GMV, WMV, CSF volume, WMH, TIV</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, Charlson comorbidity index, cognitive function, mood and depressive symptoms, educational years, BMI, blood cell count and biochemistry (fasting blood sugar, total hypercholesterolaemia, albumin, total protein, uric acid, serum creatinine, Hs‐CRP, urine analysis and dual‐energy X‐ray absorptiometry)</td><td align="center" valign="top">No difference in WMH quantification and WM volume</td><td align="center" valign="top">No difference in GMVAt‐risk group showed reduced GMV, compared to the robust group, in 13 brain regions including the cerebellum, hippocampi, middle frontal gyri, right inferior parietal lobule, precentral gyrus, left insula, anterior cingulate and middle occipital gyrus</td><td align="center" valign="top">Higher CSF volume in the at‐risk (prefrail and frail) subjects compared with the robust group</td><td align="center" valign="top">No difference in TIV volume</td><td align="center" valign="top">Slowness, weakness and low activity involved reduced GMV in the cerebellum. Weight loss was associated with both GMV reduction (the right postcentral gyrus) and increase (the right posterior cingulate) topographically different from frailty‐related regions</td></tr><tr><td align="left" valign="top">Chunga, 2016</td><td align="center" valign="top">3 T T2‐FLAIR</td><td align="center" valign="top">CMB, number of lacune, WMH</td><td align="center" valign="top">‐ Deep (basal ganglia, thalamus, internal capsule, external capsule, corpus callosum and deep/periventricular white matter), lobar (fontal, parietal, temporal and occipital regions)‐ Infratentorial categories (brainstem and cerebellum)</td><td align="center" valign="top">Age, sex, educational levels, smoking status, coronary artery disease, CKD, hypertension, DM, hyperlipidaemia, height, weight, BMI, cognitive function, mood and depressive symptoms</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">Both number and topography of CMB were associated with physical frail status, independent of age and vascular risk factors. The incidence and number of CMBs in the deep or infratentorial regions were associated with the severity of physical frailty. CMBs located in the lobar regions, either mixed with deep/infratentorial or strictly lobar CMB, were not associated with the severity of the physically frail status. The number of lacunes was significantly associated with the severity of the physical frail status. CMB located in the brainstem was significantly associated with physical frailty. The presence of CMBs in the brainstem was significantly associated with the severity of physical frailty; the presence of CMB in the brainstem was revealed as an independent factor associated with the presence of weakness</td></tr><tr><td align="left" valign="top">Ducca, 2022</td><td align="center" valign="top">3 T T2, FLAIR</td><td align="center" valign="top">WHV</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, race, educational levels, hypertension, coronary artery disease, diabetes, current smoking, stroke, cognitive status, BMI, APOEe4 status</td><td align="center" valign="top">Individuals with physical frailty have greater WHV and white matter microstructural abnormalities than nonfrails. This relationship was observed in participants without a history of stroke or dementia but did not persist when analyses were restricted to cognitively normal individuals, that is, the group of participants without MCI or dementia. WHV was significantly associated with new‐onset frailty over a 7‐year follow‐up period, even among cognitively normal adults. These results were consistent in Black and White participants and in men and women. Unlike WHV, general measures of white matter microstructural integrity were not associated with the risk of future frailty. However, secondary analyses did find that the microstructural integrity of specific white matter tracts was associated with future frailty</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td></tr><tr><td align="left" valign="top">Kant, 2019</td><td align="center" valign="top">3 T T1, FLAIR, DWI</td><td align="center" valign="top">WHV, WMH shape, lacunar infarcts</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, hypertension, cognitive status, depressive symptoms, diabetes, BMI, obesity, smoking status, stroke, American Society of Anaesthesiologists score</td><td align="center" valign="top">Frail and prefrail participants had a higher WHV compared to nonfrail participants. Prefrail participants showed a more complex shape of periventricular and confluent WMH compared to nonfrail participants</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">No between‐group differences were found in shape features of deep WMH, cerebral perfusion or presence of lacunar infarct</td></tr><tr><td align="left" valign="top">Kant, 2018</td><td align="center" valign="top">3 T T1, FLAIR</td><td align="center" valign="top">TBV, GMV, WHV, WM volume, presence of a cortical brain infarct</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, gender, BMI, DM, smoking status, hypertension, hypercholesterolaemia, cognitive status, American Society of Anaesthesiologists score</td><td align="center" valign="top">Higher WHV in frail individuals</td><td align="center" valign="top">Lower GMV in frail individuals</td><td align="center" valign="top">—</td><td align="center" valign="top">Lower TBV in frail individuals; frail individuals showed a lower global cortical thickness compared to prefrail and nonfrail individuals; however, no regional clusters of a lower cortical thickness were found</td><td align="center" valign="top">More cortical infarcts in frail individuals; individual frailty components showed a relation with a lower global grey matter volume, but this did not reach statistical significance. Furthermore, prefrail individuals had more cortical brain infarcts compared to nonfrail individuals</td></tr><tr><td align="left" valign="top">Li, 2021</td><td align="center" valign="top">3 T T1, T2, DWI</td><td align="center" valign="top">GMV, WMV, CSFV, MYV, BPV, ICV, GMF, WMF, MYF, GMV/ICV, WMV/ICV, CSF/ICV, MYV/ICV</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, BMI, educational level, cognitive status</td><td align="center" valign="top">—</td><td align="center" valign="top">Multiple regional GM volumetry showed significant correlations with the EFS. No significant correlation was found between the EFS and regional GM relaxometry. Both global volumetry and global relaxometry showed strong correlations with some domain scores of the EFS. Some regional GM volumetry showed strong negative correlations with the functional performance score. Significant negative correlations were identified between the functional performance score and the GMV of Rolandic, olfactory, rectus, cingulate, hippocampus, parahippocampal and precuneus. No notable correlations were found between regional GMV and the cognition score, general health status score, functional independence score, medication use score, nutrition score, mood score or continence score. Significant negative correlations were found between the functional independence score and the T1 value of caudate. No notable correlations were identified between the other scores and regional GM T1 values. Significant negative correlations were identified between the functional independence score and the T2 values of insula and caudate. No notable correlations were found between the other scores and regional GM T2 values. No significant correlations between the domain scores of the EFS and regional GM PD values were identified</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td></tr><tr><td align="left" valign="top">Maltais, 2019</td><td align="center" valign="top">—</td><td align="center" valign="top">WHV, WMH progression</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, educational level, DM, hypertension, hypercholesterolaemia</td><td align="center" valign="top">A significant increase in likelihood of increasing 1 point on the frailty phenotype score over 3 years with higher baseline WMH. For the progression of WMH, no significant associations were found for the continuous variable as well as the dichotomous variable (fast vs. slow progression of WMH) with frailty evolution</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td></tr><tr><td align="left" valign="top">Siejka, 2020</td><td align="center" valign="top">1.5 T T1, T2, FLAIR, GRE</td><td align="center" valign="top">WMH, SI, microbleeds</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, educational level</td><td align="center" valign="top">Higher baseline WMH was associated with a greater progression in frailty. WMH was significantly associated with progressively worsening frailty. A higher burden of baseline WMH was more strongly associated with progression of frailty</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">SI and microbleeds were not significantly associated with progression of frailty</td></tr><tr><td align="left" valign="top">Siejka, 2017</td><td align="center" valign="top">1.5 T T1, T2, FLAIR, GRE</td><td align="center" valign="top">WMH, SI, CMB</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, educational level</td><td align="center" valign="top">WMH in unadjusted models was positively associated with higher frailty scores. In final models including all brain variables, higher burden of WMH was independently associated with a higher frailty score. In fully adjusted models, WMH was associated with the motor index</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">SI and CMB in unadjusted models were positively associated with higher frailty scores. In final models including all brain variables, higher burden of SI or CMB was not associated with a higher frailty score</td></tr><tr><td align="left" valign="top">Suárez‐Méndez, 2021</td><td align="center" valign="top">0.23 T T1</td><td align="center" valign="top">MEG</td><td align="center" valign="top">Whole brain</td><td align="center" valign="top">Age, gender, hypertension, DM, dyslipidaemia, COPD/asthma, presence of osteoporosis, vertebral fracture, low Vitamin D, AF, IHD, cancer, incontinence, functional status, neuropsychological status</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">Significant group differences in relative power were found in the classical alpha (mu) and SMR frequency bands. We found no significant group differences in theta nor beta frequencies after multiple comparison correction found in the RH affecting posterior parietal areas (e.g., AG and SPL), the primary somatosensory cortex and the superior occipital cortex. Significant bilateral differences involved areas of the primary motor cortex. These regions comprise those classically associated with traditional generators of mu activity; thus henceforth, we will refer to our results within this range as mu oscillationsSignificant group differences were found in SMR relative power after multiple comparison correction. Frail participants exhibited increased SMR relative power in comparison to their robust peers. The strongest differences were found in frontal areas of the RH, including the premotor cortex, the supplementary motor area and the paracingulate gyrus</td><td align="center" valign="top">—</td></tr><tr><td align="left" valign="top">Sugimoto, 2019</td><td align="center" valign="top">1.5 T T1, T2, FLAIR</td><td align="center" valign="top">ICV, WMH, parenchyma volume, WMH/PAR</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, BMI, educational level, cognitive function, functional status, smoking status, drinking status, hypertension, DM, hyperlipidaemia, coronary artery disease, CRP, BNP, homocysteine, eGFR</td><td align="center" valign="top">Higher WMH and WMH/PAR volumes in CF individuals. WMH/PAR volume was shown to be highest among those with minimal cognitive impairment and PF. The PF/CN, pre‐PF/MCI and PF/MCI groups had significantly higher WMH/PAR volumes compared to the non‐PF/CN group. PF subjects had higher WMH volumes compared to non‐PF subjects among patients without MCI</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">Lower IC and PAR volumes in CF individuals</td><td align="center" valign="top">—</td></tr><tr><td align="left" valign="top">Nishita, 2019</td><td align="center" valign="top">3 T T1</td><td align="center" valign="top">GMV</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, education level, marital status, conditions of habitation (living alone, living with others), employment (employed, unemployed), current smoking status, hypertension, stroke, heart disease, DM, dyslipidaemia, presence of osteoporosis, chronic bronchitis and knee arthropathy</td><td align="center" valign="top">—</td><td align="center" valign="top">Volumes of GM of each region did not differ significantly among physically frail, prefrail and robust groups</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">Weakness and slowness were significantly and negatively associated with the grey matter volumes of specific regions. Weakness was significantly associated with reduced GMV in the right anterior hippocampal and amygdala clusters and the bilateral fusiform gyrus. Regions significantly associated with slowness overlapped with regions significantly associated with weakness: the bilateral anterior hippocampus and amygdala and fusiform gyrus. Slowness was associated with a reduced volume of more extensive brain regions, including the bilateral medial prefrontal and orbitofrontal cortex, inferior frontal gyrus, primary somatosensory cortex, insula, superior temporal sulcus and cerebellum</td></tr><tr><td align="left" valign="top">Zhao, 2021</td><td align="center" valign="top">3 T T1, T2, FLAIR, DWI, SWI</td><td align="center" valign="top">WMH, lacunes, CMB, EPVS‐BG</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, weight, education level, smoking, and alcohol drinking status, hypertension, stroke, coronary heart disease, DM, hyperlipidaemia, kidney disease, arthritis, migraine, depressive symptoms, sleep quality</td><td align="center" valign="top">The severity of the WMH was correlated with frailty and sleep quality</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">Participants with a higher CSVD burden were more likely to be frail. The severity of the EPVS‐BG and the number of lacunes were correlated with frailty and sleep quality. Sleep quality played a partial mediating role in the association between CSVD burden and physical frailty</td></tr><tr><td align="left" valign="top">Isernia, 2023</td><td align="center" valign="top">3 T T1‐3D, FLAIR, T2</td><td align="center" valign="top">Brain morphometry, WMH</td><td align="center" valign="top">Whole brain</td><td align="center" valign="top">Sex, age, education level, memory, attention, language</td><td align="center" valign="top">No notable associations between the frailty score and the overall volume of WMH</td><td align="center" valign="top">Frailty was shown to be correlated with decreased cortical thickness in the left supramarginal gyrus and the right rostral middle frontal gyrus</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">No notable associations between the frailty score and the volumes of subcortical areas</td></tr><tr><td align="left" valign="top">Gutiérrez‐Zúñiga, 2023</td><td align="center" valign="top">3 T T1‐3D, DTI</td><td align="center" valign="top">Grey matter measures (cortical and subcortical) and white matter tracts</td><td align="center" valign="top">Cortex, basal ganglia and each of the Desikan–Killiany regional volumes</td><td align="center" valign="top">Age, sex, medical history (number of regular medications, vascular diseases, cancer and smoking history), physical exercise in metabolic equivalents and quality of life measured by the CASP‐12 scale</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">—</td><td align="center" valign="top">The FI exhibited a negative correlation with the total volume of the cortex</td><td align="center" valign="top">The basal ganglia measurements showed a negative correlation between thalamic volumes and the FI</td></tr></tbody></table></div>Abbreviations: AF, atrial fibrillation; AG, angular gyrus; BG, basal ganglia; BMI, body mass index; BNP, B‐type natriuretic peptide; BPV, brain parenchymal volume; CF, cognitive frailty; CKD, chronic kidney disease; CMB, cerebral microbleeds; CN, cognitively normal; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; CSF, cerebrospinal fluid; CSFV, cerebral spinal fluid volume; CSVD, cerebral small vessel disease; DAN, dorsal attention network; DM, diabetes mellitus; DWI, diffusion weighted imaging; EFS, Edmonton frailty scale; eGFR, estimated glomerular filtration rate; EPVS, enlarged perivascular spaces; FLAIR, fluid‐attenuated inversion recovery; FPN, frontoparietal network; GMF, grey matter fraction (GMV/BPV); GMV, grey matter volume; GRE, gradient echo sequences; hs‐CRP, high sensitivity C‐reactive protein; ICV, intracranial volume; IFG, inferior frontal gyrus; IHD, ischemic heart disease; MCI, mildly cognitively impaired; MEG, magnetoencephalography; MFG, middle frontal gyrus; MYF, myelin fraction (MYV/BPV); MYV, myelin volume; PAR, parenchyma; PD, proton density; pDMN, posterior default mode network; PF, physical frailty; RH, right hemisphere; SI, subcortical infarct; SMA, sensory motor area; SMG, supramarginal gyrus; SMR, sensorimotor rhythm; SPL, superior parietal lobule; SVD, small vessel disease; SWI, susceptibility weighted imaging; T, tesla; TBV, total brain volume; TIV, total intracranial volume; VAN, ventral attention network; WHV, white matter hyperintensity volume; WM, white matter; WMF, white matter fraction (WMV/BPV); WMH, white matter hyperintensity; WMV, white matter volume.</transformed-table></extracted-table><extracted-table><table-id>jcsm13719-tbl-0003</table-id><table-label>TABLE 3</table-label><table-caption>A summary of findings of studies on DTI.</table-caption><table-wrap-foot>Abbreviations: AD, axial diffusivity; APOE e4, apolipoprotein e4; BMI, body mass index; DTI, diffusion tensor imaging; FA, fractional anisotropy; gFA, general factors for FA; gMD, general factors for MD; MD, mean diffusivity; RD, radial diffusivity; ROI, region of interest; WM, white matter; WMH, white matter hyperintensities.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="jcsm13719-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>A summary of findings of studies on DTI.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Field strength</th><th align="center" valign="bottom" rowspan="1" colspan="1">Covariates</th><th align="center" valign="bottom" rowspan="1" colspan="1">Studied tracts/regions</th><th align="center" valign="bottom" rowspan="1" colspan="1">FA (fractional anisotropy)</th><th align="center" valign="bottom" rowspan="1" colspan="1">MD (mean diffusivity)</th><th align="center" valign="bottom" rowspan="1" colspan="1"><sc>ad</sc> (axial diffusivity)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RD (radial diffusivity)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Avila‐Funes, 2016</td><td align="center" valign="top" rowspan="1" colspan="1">1.5 T</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, educational level, myocardial infarction, angina pectoris, stroke or hypercholesterolaemia, hypertension, diabetes, smoking status, cognitive status</td><td align="center" valign="top" rowspan="1" colspan="1">Whole brain</td><td align="center" valign="top" rowspan="1" colspan="1">Frail individuals had lower FA in extensive areas of WM</td><td align="center" valign="top" rowspan="1" colspan="1">Frail individuals had higher MD in extensive areas of WM</td><td align="center" valign="top" rowspan="1" colspan="1">Frail individuals had higher <sc>ad</sc> in extensive areas of WM</td><td align="center" valign="top" rowspan="1" colspan="1">Frail individuals had higher RD in extensive areas of WM</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ducca, 2022</td><td align="center" valign="top" rowspan="1" colspan="1">3 T</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, race, educational levels, hypertension, coronary artery disease, diabetes, current smoking, stroke, cognitive status, body mass index, APOEe4 status</td><td align="center" valign="top" rowspan="1" colspan="1">The superior longitudinal fasciculus and posterior limb of the internal capsule, as well as the genu, body and splenium of the corpus callosum</td><td align="center" valign="top" rowspan="1" colspan="1">No significant difference among cognitively normal participants</td><td align="center" valign="top" rowspan="1" colspan="1">Frailty status was associated with lower gMD</td><td align="center" valign="top" rowspan="1" colspan="1">No significant difference among cognitively normal participants</td><td align="center" valign="top" rowspan="1" colspan="1">No significant difference among cognitively normal participants</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maltais, 2020</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, educational level, diabetes mellitus, hypertension, hypercholesterolaemia, cognitive status, short physical performance battery (lower extremity functioning)</td><td align="center" valign="top" rowspan="1" colspan="1">The corona radiata, internal capsule, corpus callosum, external capsule, thalamic radiation, occipital fasciculus, longitudinal fasciculus</td><td align="center" valign="top" rowspan="1" colspan="1">No significant difference</td><td align="center" valign="top" rowspan="1" colspan="1">Increased in anterior limb of internal capsule, external capsule, posterior corona radiata, posterior thalamic radiation, superior corona radiata, superior frontal occipital fasciculus and superior longitudinal fasciculus among frail participants</td><td align="center" valign="top" rowspan="1" colspan="1">Increased AD in the anterior limb of internal capsule, external capsule, posterior corona radiata, posterior thalamic radiation, superior corona radiata, superior frontal occipital fasciculus and superior longitudinal fasciculus among frail participants</td><td align="center" valign="top" rowspan="1" colspan="1">Increased in anterior limb of internal capsule, external capsule, posterior corona radiata, posterior thalamic radiation, superior corona radiata, superior frontal occipital fasciculus and superior longitudinal fasciculus among frail participants</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tian, 2020</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, race, educational level, APOEe4 status, BMI, cardiovascular disease</td><td align="center" valign="top" rowspan="1" colspan="1">Whole brain</td><td align="center" valign="top" rowspan="1" colspan="1"><p>Higher frail score was associated with lower FA of the body of the corpus callosum and superior fronto‐occipital fasciculus</p><p>‐ The frail group had lower FA of the body of the corpus callosum and superior fronto‐occipital fasciculus at a marginal significance.</p><p>‐ Compared to the nonfrail group, the prefrail group had lower FA of the superior fronto‐occipital fasciculus and a trend toward lower FA of the body of the corpus callosum</p></td><td align="center" valign="top" rowspan="1" colspan="1"><p>‐ A higher frail score was associated with higher MD of the medial frontal cortex, putamen, caudate, thalamus and anterior cingulate cortex</p><p>‐ Compared to the nonfrail group, the frail group had higher MD of the medial frontal cortex, putamen, caudate, thalamus and anterior cingulate cortex</p><p>‐ Compared to the nonfrail group, the prefrail group had significantly higher MD of the putamen</p></td><td align="center" valign="top" rowspan="1" colspan="1">No significant difference</td><td align="center" valign="top" rowspan="1" colspan="1">No significant difference</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gutiérrez‐Zúñiga, 2023</td><td align="center" valign="top" rowspan="1" colspan="1">3 T</td><td align="center" valign="top" rowspan="1" colspan="1">Age, sex, medical history (number of regular medications, vascular diseases, cancer and smoking history), physical exercise in metabolic equivalents and quality of life measured by the CASP‐12 scale</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">With higher FI there was a decrease in FA in corpus callosum and superior longitudinal fasciculus and anterior corona radiata in both hemispheres</td><td align="center" valign="top" rowspan="1" colspan="1">With higher FI there was an increase in MD in corpus callosum and superior longitudinal fasciculus and anterior corona radiata in both hemispheres</td><td align="center" valign="top" rowspan="1" colspan="1">Not examined</td><td align="center" valign="top" rowspan="1" colspan="1">Not examined</td></tr></tbody></table><table-wrap-foot id="jcsm13719-ntgp-0004"><fn id="jcsm13719-note-0005"><p>Abbreviations: AD, axial diffusivity; APOE e4, apolipoprotein e4; BMI, body mass index; DTI, diffusion tensor imaging; FA, fractional anisotropy; gFA, general factors for FA; gMD, general factors for MD; MD, mean diffusivity; RD, radial diffusivity; ROI, region of interest; WM, white matter; WMH, white matter hyperintensities.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>TABLE 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">A summary of findings of studies on DTI.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom">Study</th><th align="center" valign="bottom">Field strength</th><th align="center" valign="bottom">Covariates</th><th align="center" valign="bottom">Studied tracts/regions</th><th align="center" valign="bottom">FA (fractional anisotropy)</th><th align="center" valign="bottom">MD (mean diffusivity)</th><th align="center" valign="bottom">ad (axial diffusivity)</th><th align="center" valign="bottom">RD (radial diffusivity)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top">Avila‐Funes, 2016</td><td align="center" valign="top">1.5 T</td><td align="center" valign="top">Age, sex, educational level, myocardial infarction, angina pectoris, stroke or hypercholesterolaemia, hypertension, diabetes, smoking status, cognitive status</td><td align="center" valign="top">Whole brain</td><td align="center" valign="top">Frail individuals had lower FA in extensive areas of WM</td><td align="center" valign="top">Frail individuals had higher MD in extensive areas of WM</td><td align="center" valign="top">Frail individuals had higher ad in extensive areas of WM</td><td align="center" valign="top">Frail individuals had higher RD in extensive areas of WM</td></tr><tr><td align="left" valign="top">Ducca, 2022</td><td align="center" valign="top">3 T</td><td align="center" valign="top">Age, sex, race, educational levels, hypertension, coronary artery disease, diabetes, current smoking, stroke, cognitive status, body mass index, APOEe4 status</td><td align="center" valign="top">The superior longitudinal fasciculus and posterior limb of the internal capsule, as well as the genu, body and splenium of the corpus callosum</td><td align="center" valign="top">No significant difference among cognitively normal participants</td><td align="center" valign="top">Frailty status was associated with lower gMD</td><td align="center" valign="top">No significant difference among cognitively normal participants</td><td align="center" valign="top">No significant difference among cognitively normal participants</td></tr><tr><td align="left" valign="top">Maltais, 2020</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, educational level, diabetes mellitus, hypertension, hypercholesterolaemia, cognitive status, short physical performance battery (lower extremity functioning)</td><td align="center" valign="top">The corona radiata, internal capsule, corpus callosum, external capsule, thalamic radiation, occipital fasciculus, longitudinal fasciculus</td><td align="center" valign="top">No significant difference</td><td align="center" valign="top">Increased in anterior limb of internal capsule, external capsule, posterior corona radiata, posterior thalamic radiation, superior corona radiata, superior frontal occipital fasciculus and superior longitudinal fasciculus among frail participants</td><td align="center" valign="top">Increased AD in the anterior limb of internal capsule, external capsule, posterior corona radiata, posterior thalamic radiation, superior corona radiata, superior frontal occipital fasciculus and superior longitudinal fasciculus among frail participants</td><td align="center" valign="top">Increased in anterior limb of internal capsule, external capsule, posterior corona radiata, posterior thalamic radiation, superior corona radiata, superior frontal occipital fasciculus and superior longitudinal fasciculus among frail participants</td></tr><tr><td align="left" valign="top">Tian, 2020</td><td align="center" valign="top">—</td><td align="center" valign="top">Age, sex, race, educational level, APOEe4 status, BMI, cardiovascular disease</td><td align="center" valign="top">Whole brain</td><td align="center" valign="top">Higher frail score was associated with lower FA of the body of the corpus callosum and superior fronto‐occipital fasciculus‐ The frail group had lower FA of the body of the corpus callosum and superior fronto‐occipital fasciculus at a marginal significance.‐ Compared to the nonfrail group, the prefrail group had lower FA of the superior fronto‐occipital fasciculus and a trend toward lower FA of the body of the corpus callosum</td><td align="center" valign="top">‐ A higher frail score was associated with higher MD of the medial frontal cortex, putamen, caudate, thalamus and anterior cingulate cortex‐ Compared to the nonfrail group, the frail group had higher MD of the medial frontal cortex, putamen, caudate, thalamus and anterior cingulate cortex‐ Compared to the nonfrail group, the prefrail group had significantly higher MD of the putamen</td><td align="center" valign="top">No significant difference</td><td align="center" valign="top">No significant difference</td></tr><tr><td align="left" valign="top">Gutiérrez‐Zúñiga, 2023</td><td align="center" valign="top">3 T</td><td align="center" valign="top">Age, sex, medical history (number of regular medications, vascular diseases, cancer and smoking history), physical exercise in metabolic equivalents and quality of life measured by the CASP‐12 scale</td><td align="center" valign="top">—</td><td align="center" valign="top">With higher FI there was a decrease in FA in corpus callosum and superior longitudinal fasciculus and anterior corona radiata in both hemispheres</td><td align="center" valign="top">With higher FI there was an increase in MD in corpus callosum and superior longitudinal fasciculus and anterior corona radiata in both hemispheres</td><td align="center" valign="top">Not examined</td><td align="center" valign="top">Not examined</td></tr></tbody></table></div>Abbreviations: AD, axial diffusivity; APOE e4, apolipoprotein e4; BMI, body mass index; DTI, diffusion tensor imaging; FA, fractional anisotropy; gFA, general factors for FA; gMD, general factors for MD; MD, mean diffusivity; RD, radial diffusivity; ROI, region of interest; WM, white matter; WMH, white matter hyperintensities.</transformed-table></extracted-table><extracted-table><table-id>jcsm13719-tbl-0004</table-id><table-label>TABLE 4</table-label><table-caption>A summary of findings of studies on fMRI.</table-caption><table-wrap-foot>Abbreviations: ASA, American Society of Anaesthesiologists; BMI, body mass index; Cad, coronary artery disease; CCI, Charlson comorbidity index; CHF, congestive heart failure; FC, functional connectivity; fMRI, functional magnetic resonance imaging; GPT, Grooved Pegboard Test; N/A, not applicable; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; Rs, resting state; SMA, supplementary motor area; TMT‐A, Trail‐Making‐Test Part A.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="jcsm13719-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>A summary of findings of studies on fMRI.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Tesla sequence</th><th align="center" valign="bottom" rowspan="1" colspan="1">Brain areas</th><th align="center" valign="bottom" rowspan="1" colspan="1">Connectivity/activation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Covariates</th><th align="center" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Lammers, 2020</td><td align="center" valign="top" rowspan="1" colspan="1">3 T</td><td align="center" valign="top" rowspan="1" colspan="1">SMA, pre‐SMA</td><td align="center" valign="top" rowspan="1" colspan="1">Rs‐FC</td><td align="center" valign="top" rowspan="1" colspan="1">Sex, age, max. functional independence, ASA score, C<sc>ad</sc>, CHF, malignoma, diabetes, smoking status, nutritional status, CCI, BMI, cognitive status, depressive symptoms, albumin, NT‐proBNP</td><td align="center" valign="top" rowspan="1" colspan="1">There was a notable distinction in functional connectivity within the SMA between robust (nonfrail) patients and frail and prefrail patients, whereas no significant difference was observed between frail and prefrail patients. Frail patients had the lowest functional connectivity compared to functionally robust patients. There was a notable distinction in functional connectivity within the SMA between robust (nonfrail) patients and frail and prefrail patients, whereas no significant difference was observed between frail and prefrail patients. Frail patients had the lowest functional connectivity compared to functionally robust patients. There was no significant difference in functional connectivity between correlated and anticorrelated brain regions among frail patients. No correlations were observed between frailty and functional connectivity in the network prior to SMA. Functional connectivity in the pre‐SMA network was found to be significantly cortical region dependent and notably diminished in subjects with higher MMSE scores among the confounding variables. Functional connectivity was found to be associated with GPT performance alone, when correlated brain regions were examined individually; functional robustness and frailty were not influenced. Functional connectivity in anticorrelated regions of the SMA network was similarly associated with TMT‐A and partial performance but not with functional robustness or frailty</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lammers, 2022</td><td align="center" valign="top" rowspan="1" colspan="1">3 T</td><td align="center" valign="top" rowspan="1" colspan="1">SMA, pre‐SMA</td><td align="center" valign="top" rowspan="1" colspan="1">Rs‐FC</td><td align="center" valign="top" rowspan="1" colspan="1">Sex, age, BMI, cognitive status, nutritional status, CCI, ASA score, stroke, malignant disease, albumin, NT‐proBNP, creatinine, haemoglobin, anaesthesia type, type of surgery, length of hospital stay, ICU admission rate, length of ICU stay, presence of postoperative complications, severity of surgical complication, presence of postoperative delirium</td><td align="center" valign="top" rowspan="1" colspan="1">The authors of the study examined 120 cognitively normal patients which were undergoing various elective surgeries. Fourteen days prior to and 3 months subsequent to the procedure, functional neuroimaging changes were evaluated by introducing dynamic frailty states. After surgery, physical improvement was noted in 19 patients, progression to (pre)frailty was documented in 24 patients and no noticeable shift was found in 77 individuals. Postoperative transition types that were more unfavourable were related with decreased functional connectivity in the pre‐SMA network. An exploratory analysis suggested that the association was restricted to patients who were prefrail at baseline. In the initial analysis, no correlation was found between the kind of transition and the functional connectivity of SMAs. Transition from prefrailty to robustness was linked with greater functional connectivity in an exploratory analysis, and advancement in robust patients was associated with greater SMA network segmentation. Dysfunctions of cortical networks implicated in higher cognitive control of mobility are related with postoperative transitions between frailty stages, according to the findings. As part of strategies to avoid frailty, neurofeedback or brain stimulation may be utilised to target the pre‐SMA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Suárez‐Méndez, 2020</td><td align="center" valign="top" rowspan="1" colspan="1">0.23 T</td><td align="center" valign="top" rowspan="1" colspan="1">Key areas for motor function and the central processing of proprioception (i.e., SMG, SPL, AG and sensorimotor cortex (precentral and postcentral gyri))</td><td align="center" valign="top" rowspan="1" colspan="1">Rs‐FC</td><td align="center" valign="top" rowspan="1" colspan="1">Age, gender, functional status, neuropsychological status</td><td align="center" valign="top" rowspan="1" colspan="1"><p>After correction for multiple comparisons, three significant clusters of FC differences emerged: two associated with seeds situated in the right hemisphere (AG and SPL) and one pertaining to the bilateral SMG. The direction of FC disruptions was consistent: the frail group consistently displayed diminished synchronization between the clusters and the seeds in the upper beta frequency band. To begin with, a diminished FC was observed in the vicinity of the right AG and various regions, such as the right motor cortex, precuneus, posterior cingulate cortex and sensorimotor cortex (precentral and postcentral gyri)</p><p>Additionally, a diminished frontal cortex (FC) is observed in the vicinity of the right SPL and the anterior regions of the left hemisphere, including the frontal pole, the anterior cingulate, the lateral and medial frontal areas (e.g., premotor cortex) and the left temporal pole</p><p>In conclusion, FC was diminished in the bilateral cingulate cortex, areas of the sensorimotor cortex, the right precuneus, and the left premotor cortex (IFG and FMG), SMA and the bilateral SMG.</p><p>In the alpha, mu, and low beta frequency bands, as well as when the sensorimotor cortex was employed as a seed, no statistically significant variations were observed</p><p>In comparison to their robust counterparts, the intranetwork mean FC was overall lower among frail older adults. To be more specific, participants who were frail demonstrated a diminished FC in the upper beta band across the FPN, pDMN and VAN. Moreover, within the upper beta band, the DAN exhibited a strong trend in the same direction (i.e., toward a lower FC in the frail group)</p></td></tr></tbody></table><table-wrap-foot id="jcsm13719-ntgp-0005"><fn id="jcsm13719-note-0006"><p>Abbreviations: ASA, American Society of Anaesthesiologists; BMI, body mass index; C<sc>ad</sc>, coronary artery disease; CCI, Charlson comorbidity index; CHF, congestive heart failure; FC, functional connectivity; fMRI, functional magnetic resonance imaging; GPT, Grooved Pegboard Test; N/A, not applicable; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; Rs, resting state; SMA, supplementary motor area; TMT‐A, Trail‐Making‐Test Part A.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>TABLE 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">A summary of findings of studies on fMRI.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom">Study</th><th align="center" valign="bottom">Tesla sequence</th><th align="center" valign="bottom">Brain areas</th><th align="center" valign="bottom">Connectivity/activation</th><th align="center" valign="bottom">Covariates</th><th align="center" valign="bottom">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top">Lammers, 2020</td><td align="center" valign="top">3 T</td><td align="center" valign="top">SMA, pre‐SMA</td><td align="center" valign="top">Rs‐FC</td><td align="center" valign="top">Sex, age, max. functional independence, ASA score, Cad, CHF, malignoma, diabetes, smoking status, nutritional status, CCI, BMI, cognitive status, depressive symptoms, albumin, NT‐proBNP</td><td align="center" valign="top">There was a notable distinction in functional connectivity within the SMA between robust (nonfrail) patients and frail and prefrail patients, whereas no significant difference was observed between frail and prefrail patients. Frail patients had the lowest functional connectivity compared to functionally robust patients. There was a notable distinction in functional connectivity within the SMA between robust (nonfrail) patients and frail and prefrail patients, whereas no significant difference was observed between frail and prefrail patients. Frail patients had the lowest functional connectivity compared to functionally robust patients. There was no significant difference in functional connectivity between correlated and anticorrelated brain regions among frail patients. No correlations were observed between frailty and functional connectivity in the network prior to SMA. Functional connectivity in the pre‐SMA network was found to be significantly cortical region dependent and notably diminished in subjects with higher MMSE scores among the confounding variables. Functional connectivity was found to be associated with GPT performance alone, when correlated brain regions were examined individually; functional robustness and frailty were not influenced. Functional connectivity in anticorrelated regions of the SMA network was similarly associated with TMT‐A and partial performance but not with functional robustness or frailty</td></tr><tr><td align="left" valign="top">Lammers, 2022</td><td align="center" valign="top">3 T</td><td align="center" valign="top">SMA, pre‐SMA</td><td align="center" valign="top">Rs‐FC</td><td align="center" valign="top">Sex, age, BMI, cognitive status, nutritional status, CCI, ASA score, stroke, malignant disease, albumin, NT‐proBNP, creatinine, haemoglobin, anaesthesia type, type of surgery, length of hospital stay, ICU admission rate, length of ICU stay, presence of postoperative complications, severity of surgical complication, presence of postoperative delirium</td><td align="center" valign="top">The authors of the study examined 120 cognitively normal patients which were undergoing various elective surgeries. Fourteen days prior to and 3 months subsequent to the procedure, functional neuroimaging changes were evaluated by introducing dynamic frailty states. After surgery, physical improvement was noted in 19 patients, progression to (pre)frailty was documented in 24 patients and no noticeable shift was found in 77 individuals. Postoperative transition types that were more unfavourable were related with decreased functional connectivity in the pre‐SMA network. An exploratory analysis suggested that the association was restricted to patients who were prefrail at baseline. In the initial analysis, no correlation was found between the kind of transition and the functional connectivity of SMAs. Transition from prefrailty to robustness was linked with greater functional connectivity in an exploratory analysis, and advancement in robust patients was associated with greater SMA network segmentation. Dysfunctions of cortical networks implicated in higher cognitive control of mobility are related with postoperative transitions between frailty stages, according to the findings. As part of strategies to avoid frailty, neurofeedback or brain stimulation may be utilised to target the pre‐SMA</td></tr><tr><td align="left" valign="top">Suárez‐Méndez, 2020</td><td align="center" valign="top">0.23 T</td><td align="center" valign="top">Key areas for motor function and the central processing of proprioception (i.e., SMG, SPL, AG and sensorimotor cortex (precentral and postcentral gyri))</td><td align="center" valign="top">Rs‐FC</td><td align="center" valign="top">Age, gender, functional status, neuropsychological status</td><td align="center" valign="top">After correction for multiple comparisons, three significant clusters of FC differences emerged: two associated with seeds situated in the right hemisphere (AG and SPL) and one pertaining to the bilateral SMG. The direction of FC disruptions was consistent: the frail group consistently displayed diminished synchronization between the clusters and the seeds in the upper beta frequency band. To begin with, a diminished FC was observed in the vicinity of the right AG and various regions, such as the right motor cortex, precuneus, posterior cingulate cortex and sensorimotor cortex (precentral and postcentral gyri)Additionally, a diminished frontal cortex (FC) is observed in the vicinity of the right SPL and the anterior regions of the left hemisphere, including the frontal pole, the anterior cingulate, the lateral and medial frontal areas (e.g., premotor cortex) and the left temporal poleIn conclusion, FC was diminished in the bilateral cingulate cortex, areas of the sensorimotor cortex, the right precuneus, and the left premotor cortex (IFG and FMG), SMA and the bilateral SMG.In the alpha, mu, and low beta frequency bands, as well as when the sensorimotor cortex was employed as a seed, no statistically significant variations were observedIn comparison to their robust counterparts, the intranetwork mean FC was overall lower among frail older adults. To be more specific, participants who were frail demonstrated a diminished FC in the upper beta band across the FPN, pDMN and VAN. Moreover, within the upper beta band, the DAN exhibited a strong trend in the same direction (i.e., toward a lower FC in the frail group)</td></tr></tbody></table></div>Abbreviations: ASA, American Society of Anaesthesiologists; BMI, body mass index; Cad, coronary artery disease; CCI, Charlson comorbidity index; CHF, congestive heart failure; FC, functional connectivity; fMRI, functional magnetic resonance imaging; GPT, Grooved Pegboard Test; N/A, not applicable; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; Rs, resting state; SMA, supplementary motor area; TMT‐A, Trail‐Making‐Test Part A.</transformed-table></extracted-table><extracted-table><table-id>jcsm13719-tbl-0005</table-id><table-label>TABLE 5</table-label><table-caption>A summary of findings of the study on PET scan.</table-caption><table-wrap-foot>Abbreviations: ApoE e4, apolipoprotein E e4; FI, frailty index; MAPT, Multidomain Alzheimer's Preventive Trial; PET, positron emission tomography; SUVR, standard uptake value ratios.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="jcsm13719-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>A summary of findings of the study on PET scan.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Analysis details</th><th align="center" valign="bottom" rowspan="1" colspan="1">Covariates</th><th align="center" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Maltais, 2019</td><td align="center" valign="top" rowspan="1" colspan="1">PET data gathering begun 50 min after [18F]‐florbetapir was injected at a mean rate of 4 MBq/kg weight. The mean duration from the PET examination to the clinical assessment in close proximity to the PET was 76.3 days (standard deviation: 40.6)</td><td align="center" valign="top" rowspan="1" colspan="1">Age, gender, educational level, cognitive status, MAPT group allocation, ApoE e4 genotype</td><td align="center" valign="top" rowspan="1" colspan="1">The mean cortical Aβ load was not found to be associated with a FI derived from noncognitive measures. Nevertheless, in community‐dwelling older adults, Aβ in both the anterior and posterior putamen was found to be associated with FI severity in both cross‐sectional and prospective studies. Furthermore, the progressive accumulation of Aβ in the precuneus region was found to be correlated with a heightened severity of frailty. Frailty following an incident was not associated with cortical or regional Aβ. This research demonstrated that cerebral Aβ accumulation may influence the progression of frailty in elderly individuals over time</td></tr></tbody></table><table-wrap-foot id="jcsm13719-ntgp-0006"><fn id="jcsm13719-note-0007"><p>Abbreviations: ApoE e4, apolipoprotein E e4; FI, frailty index; MAPT, Multidomain Alzheimer's Preventive Trial; PET, positron emission tomography; SUVR, standard uptake value ratios.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>TABLE 5<div xmlns="http://www.w3.org/1999/xhtml" class="caption">A summary of findings of the study on PET scan.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="center"/><col align="center"/><col align="center"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom">Study</th><th align="center" valign="bottom">Analysis details</th><th align="center" valign="bottom">Covariates</th><th align="center" valign="bottom">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top">Maltais, 2019</td><td align="center" valign="top">PET data gathering begun 50 min after [18F]‐florbetapir was injected at a mean rate of 4 MBq/kg weight. The mean duration from the PET examination to the clinical assessment in close proximity to the PET was 76.3 days (standard deviation: 40.6)</td><td align="center" valign="top">Age, gender, educational level, cognitive status, MAPT group allocation, ApoE e4 genotype</td><td align="center" valign="top">The mean cortical Aβ load was not found to be associated with a FI derived from noncognitive measures. Nevertheless, in community‐dwelling older adults, Aβ in both the anterior and posterior putamen was found to be associated with FI severity in both cross‐sectional and prospective studies. Furthermore, the progressive accumulation of Aβ in the precuneus region was found to be correlated with a heightened severity of frailty. Frailty following an incident was not associated with cortical or regional Aβ. This research demonstrated that cerebral Aβ accumulation may influence the progression of frailty in elderly individuals over time</td></tr></tbody></table></div>Abbreviations: ApoE e4, apolipoprotein E e4; FI, frailty index; MAPT, Multidomain Alzheimer's Preventive Trial; PET, positron emission tomography; SUVR, standard uptake value ratios.</transformed-table></extracted-table></extracted-tables-set>